RRAS and juvenile myelomonocytic leukemia: The RRAS p.Q87L variant, which has been previously shown to increase MAPK activity and inhibit apoptosis34,35, has been reported in rapidly progressive JMML, and other germline variants in RRAS have been identified in Noonan Syndrome and JMML36.